Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19

NCT05996744 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT05996744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05996744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Single-Arm, Open-label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Obeldesivir in Pediatric Participants With COVID-19
Lead sponsor
Gilead Sciences
Phase
Phase 2/3
Overall status
Terminated
Start date
December 26, 2023
Completion date
February 23, 2024
Enrollment
3 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19